Stephen Hahn, AP

Scoop: A Penn Parkin­son's spin­out goes dark as ex-FDA com­mish Hahn jumps off board

Not even a for­mer FDA com­mis­sion­er could keep this small biotech alive. Neu­rol­o­gy-fo­cused Black­fynn, a 2015 Penn spin­out, has gone dark, End­points News has learned.

The biotech seemed to hold enough promise for for­mer FDA com­mis­sion­er Stephen Hahn to sign on to its board as his first move af­ter leav­ing the agency in Jan­u­ary 2021. He joined the board in Feb­ru­ary 2021 but has since left, a rep­re­sen­ta­tive for Hahn con­firmed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.